Post-Hoc Analysis of ARASENS Reinforces Use of Darolutamide/ADT/Docetaxel Combo as SOC in mHSPC
New data about ARASENS trial: it seem... - Advanced Prostate...
New data about ARASENS trial: it seems to work well after longer observation
Written by
Maxone73
To view profiles and participate in discussions please or .
Read more about...
6 Replies
•
excellent for newly diagnosed and HSPC. I wonder if would be similar for ongoing daro and ADT and still hormone sensitive?
I won’t try chemo yet as I am thoroughly enjoying pBAT.
hopefully good news for me...as I am on Arasens
Yes, it appears ARASENS is valid for the recurrent as well as de novo mHSPC:
"In ARASENS, the treatment effect of darolutamide on OS was favourable in patients with de novo (HR 0.71; 95% CI 0.59 to 0.85) and recurrent (HR 0.61; 95% CI 0.35 to 1.05) metastatic hormone-sensitive prostate cancer" .
From esmo.org/oncology-news/daro...
I wonder if a case can be made for just daro+ADT for the recurrent?
Not what you're looking for?
You may also like...
FDA Approves Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
the ARASENS trial.
https://www.onclive.com/view/fda-and-ema-approval-sought-for-darolutamide-plus
Duke \"CHAMP\" trial, it's working after 2nd treatment
are so far less than the Docetaxel, and the blood work all improving....
225Ac-PSMA-I&T works well even after Pluvicto in small trial
Xerostomia.
Phase III trials will likely follow....
Another victory for \"triplet\"therapy for newly diagnosed metastatic men.
low volume).
Similarly, the triplet of darolutamide+docetaxel+ADT, started simultaneously,...
benefit of taking a break from Lupron and using darolutamide alone?
be a benefit to forgoing Lupron and using Darolutamide as primary, allowing testosterone to recover...